Hybridoma cell strain and anti-hydrochloric acid clenbuterol monoclonal antibody prepared from hybridoma cell strain

Abstract

The invention provides a hybridoma cell strain and an anti-hydrochloric acid clenbuterol monoclonal antibody prepared from the hybridoma cell strain and belongs to the technical field of immunochemistry. The hybridoma cell strain 6G11 generates the anti-hydrochloric acid clenbuterol monoclonal antibody 6G11'. The invention also provides a method for preparing the anti-hydrochloric acid clenbuterol monoclonal antibody 6G11', which comprises the following steps of: preparing an immunogen and a coating antigen; animal immunization; selecting immune rat serum; preparing hybridoma cells; and collecting and purifying the anti-hydrochloric acid clenbuterol monoclonal antibody 6G11'. The anti-hydrochloric acid clenbuterol monoclonal antibody with strong specificity through the rat hybridoma cell strain 6G11, has low crossing reaction rate with the salbutamol and ractopamine, can be massively produced, and can be used for preparing immunology detecting agents, such as an immunoassay kit for detecting clenbuterol hydrochloride, a colloidal gold test strip and the like so as to fast and sensitively detect clenbuterol hydrochloride medicament residue in urine, muscles and internal organs.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

AI Technical Summary

Benefits of technology

This patented technology allows us to produce very small amounts (<1 milligram) of an active ingredient called clonidone that blocks nerve impulse transmission at certain sites on brain cells. These tiny particles could potentially help treat neurologically related conditions such as Parkinson’s disease or Alzheimer's diseases.

Problems solved by technology

This patents discusses different ways how drugs likeclenevent® or other medications are being given up overweight due to their side effects when taken regularly without adequate monitoring during therapy sessions. These agents have been found to cause harmful deposits within the patient's gastrointestinal tract leading to various complications including dysfunctional bradycardics and pulmonephritis syndrome. To address these issues, there is an increasing interest among manufacturers who want to develop effective techniques for identifying residue formation from animal sources while minimizing any potential negative impact upon humans.

Images